CEFYBO   02669
CENTRO DE ESTUDIOS FARMACOLOGICOS Y BOTANICOS
Unidad Ejecutora - UE
congresos y reuniones científicas
Título:
Ischemia Reperfusion Injury in Human Kidney-Pancreas Transplantation: Protection by α-Lipoc Acid Require the Treatment of Both The Donor and The Recipient
Autor/es:
AMBROSI NELLA; GUERRIERI DIEGO; PETRONI JORGELINA; ARROSAGARAY ; UVA PABLO; CHULUYAN EDUARDO; INCARDONA CLAUDIO; CASADEI DOMINGO
Reunión:
Congreso; World Transplant Congress 2014; 2014
Resumen:
Experimental studies indicate that ALA would
have a beneficial effect in transplanted patients
through a reduction of the inflammatory
response. Previously, we have described that the administration of ALA to donor
and recipient of patients undergoing simultaneous kidney and pancreas
transplantation reduces inflammatory mediators and pancreatic enzymes. The aim
of this study was to further evaluate the effect of the administration of ALA
in diabetic patients undergoing simultaneous kidney and pancreas
transplantation. At this time we evaluated the effect of the administration of
ALA only on recipients and we compared the results with those obtained by
treating the donor and the recipients. Methods: 27 kidney-pancreas transplant
patients were included. The clinical and research activities being reported are
consistent with the Principles of the Declaration of Istanbul as outlined in
the ?Declaration of Istanbul on Organ Trafficking and Transplant Tourism?. This
study was approved by an Institutional Review Board.
The administration of ALA (600 mg, iv) was
performed on the deceased donor at the time of ablation and recipients during
the surgical procedure (DR group), or only on the recipients (R group). Blood
samples were obtained at the beginning, the end, 12 h after the surgery and
every one or two days after transplant. Serum cytokines were quantified by flow
cytometry with a Cytometric Bead Array. The level of amylase, lipase, glucose,
urea and creatinine were used as markers of organ function.Serum levels of SLPI
(secretory leukocyte proteinase inhibitor) and PAP (pancreatitis associated protein)
were measured by ELISA. The expression of inflammatory genes was analyzed by
RT-PCR in renal biopsies taken at the end of surgery. Treatment with ALA have a
protective effect on simultaneous kidney-pancreas transplant patients since it
reduces amylase
and lipase and also pro-inflammatory mediators
in serum and biopsies. The protective effect is more pronounced when both donor
and recipient are treated with ALA.